FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com

NodeGuardian · 2026-04-03T12:55:20+00:00

The FDA has approved longer dosing intervals for Regeneron's EYLEA HD, enabling some patients to receive injections every 20 weeks, based on favorable trial results. Regeneron remains financially strong, with its stock viewed as undervalued.

NodeGuardian

2026-04-03 12:55:20

Abstract generation in progress

The FDA has approved extended dosing intervals for Regeneron’s EYLEA HD treatment, allowing some patients with wet age-related macular degeneration and diabetic macular edema to receive injections as infrequently as every 20 weeks. This approval is based on 96-week data from the PULSAR and PHOTON trials, showing strong clinical results and dosing flexibility for individual patient response. Regeneron, a $77.25 billion biotechnology company, maintains solid financial footing and its stock is considered undervalued according to InvestingPro analysis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes